Photo of Catherine L. Nutt,   B.S. Ph.D.

Catherine L. Nutt, B.S. Ph.D.

Massachusetts General Hospital

Massachusetts General Hospital


cnutt@partners.org

Catherine L. Nutt, B.S. Ph.D.

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Pathology, Harvard Medical School
  • Assistant Molecular Pathologist, Molecular Pathology Unit, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

The research interest of our laboratory is the biological and clinical implications of brain tumor heterogeneity. In particular, we are analyzing glial tumor samples for cellular and genetic differences within each of: distinct pathologic subgroups, distinct molecular genetic subgroups, and groups of patients who have responded to treatment in a unique or distinct fashion. Furthermore, we are pursuing the more translational-specific aim of developing biomarkers for these distinctions.

Publications

Powered by Harvard Catalyst
  • Betensky RA, Szymonifka J, Lee EQ, Nutt CL, Batchelor TT. Computationally simple analysis of matched, outcome-based studies of ordinal disease states. Stat Med 2015; 34:2514-27. PubMed
  • Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Cosper AK, Dias-Santagata D, Nutt CL, Iafrate AJ, Louis DN. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53. J Neuropathol Exp Neurol 2011; 70:110-5. PubMed
  • Gordon FE, Nutt CL, Cheunsuchon P, Nakayama Y, Provencher KA, Rice KA, Zhou Y, Zhang X, Klibanski A. Increased expression of angiogenic genes in the brains of mouse meg3-null embryos. Endocrinology 2010; 151:2443-52. PubMed
  • Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathol 2010; 119:509-11. PubMed
  • Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, Aldape K. A multigene predictor of outcome in glioblastoma. 2010; 12:49-57. PubMed
  • Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 2009; 15:4622-9. PubMed
  • Lun XQ,Jang JH,Tang N,Deng H,Head R,Bell JC,Stojdl DF,Nutt CL,Senger DL,Forsyth PA,McCart JA. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009; 15:2777-88. PubMed
  • de la Iglesia N,Konopka G,Lim KL,Nutt CL,Bromberg JF,Frank DA,Mischel PS,Louis DN,Bonni A. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J Neurosci 2008; 28:5870-8. PubMed
  • Mueller W, Nutt CL, Ehrich M, Riemenschneider MJ, von Deimling A, van den Boom D, Louis DN. Downregulation of RUNX3 and TES by hypermethylation in glioblastoma. Oncogene 2006; 26:583-93. PubMed
  • Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006; 65:1181-8. PubMed
  • Rousseau A, Nutt CL, Betensky RA, Iafrate AJ, Han M, Ligon KL, Rowitch DH, Louis DN. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 2006; 65:1149-56. PubMed
  • Nutt CL. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg Focus 2006; 19:E2. PubMed
Hide